Snyder Douglas B. 4

4 · GW PHARMACEUTICALS PLC · Filed Mar 4, 2021

Form 4

Period: 2021-03-02

Chief Legal Officer

Transactions

Award
Share Options
2021-03-02+72,258→ 72,258 total
Exercise: $0.00→ Ordinary Shares (72,258 underlying)
Award
Share Options
2021-03-02+45,360→ 45,360 total
Exercise: $0.00→ Ordinary Shares (45,360 underlying)

Footnotes (6)

[F1]Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied.
[F2]Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021.
[F3]Granted pursuant to the Issuer's Long-Term Incentive Plan.
[F4]These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting.
[F5]Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc.
[F6]The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4.

Documents

1 file